PMN Stock Price, ProMIS Neurosciences, . Quote, Chart

Market Summary

USD1.79-0.21

Delayedas of 17 May 2024, 09:45 am

-10.50%

PMN Stock Price

View Fullscreen

PMN RSI Chart

PMN Valuation

Market Cap

37.9M

Price/Earnings (Trailing)

-3.2

Price/Free Cashflow

-2.04

PMN Price/Earnings (Trailing)

PMN Profitability

Return on Equity

-15.4K%

Return on Assets

-334.05%

Free Cashflow Yield

-48.98%

PMN Fundamentals

PMN Earnings

Earnings (TTM)

-11.9M

Earnings Growth (Yr)

27.41%

Earnings Growth (Qtr)

-0.55%

Breaking Down PMN Revenue

52 Week Range

1.96

(Low)(High)

Last 7 days

11.7%

Last 30 days

0.5%

Last 90 days

1.0%

How does PMN drawdown profile look like?

PMN Financial Health

Current Ratio

1.34

PMN Investor Care

Shares Dilution (1Y)

121.01%

Diluted EPS (TTM)

-0.71

Tracking the Latest Insider Buys and Sells of ProMIS Neurosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 23, 2023	farfel gail m	acquired	-	-	53,192	chief executive officer
Aug 23, 2023	milbury max a.	acquired	-	-	13,297	principal accounting officer
Aug 23, 2023	malenfant gavin t.	acquired	-	-	2,660	chief operating officer
Aug 23, 2023	kirwin patrick d.	acquired	-	-	11,000	-
Aug 23, 2023	cashman neil	acquired	-	-	10,643	chief scientific officer
Dec 16, 2022	williams eugene	bought	9,290	4.645	2,000	-
Dec 15, 2022	kirwin patrick d.	bought	9,020	4.51	2,000	-
Dec 14, 2022	farfel gail m	bought	4,940	4.94	1,000	chief executive officer
Dec 13, 2022	kirwin patrick d.	bought	4,870	4.87	1,000	-
Dec 12, 2022	williams eugene	bought	5,075	5.075	1,000	-

Which funds bought or sold PMN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	1,266	3,182	-%
May 15, 2024	Ally Bridge Group (NY) LLC	reduced	-0.66	797,127	2,023,800	1.12%
May 15, 2024	Northeast Financial Consultants Inc	unchanged	-	76,000	191,000	0.01%
May 15, 2024	SPHERA FUNDS MANAGEMENT LTD.	added	-	1,393,880	3,503,030	0.49%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	273	273	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	1,000	-%
May 14, 2024	Fiduciary Trust Co	unchanged	-	15,206	38,215	-%
May 14, 2024	Affinity Asset Advisors, LLC	unchanged	-	202,128	507,980	0.06%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	unchanged	-	147	599	-%
May 13, 2024	BANK OF MONTREAL /CAN/	new	-	59,821	59,821	-%

Are Funds Buying or Selling PMN?

Are funds buying PMN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMN

No. of Funds

Unveiling ProMIS Neurosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 05, 2024	sphera funds management ltd.	9.99%	1,892,474	SC 13G/A
Jan 02, 2024	sclar jeremy m.	17.4%	3,581,701	SC 13G/A
Dec 27, 2023	gordon michael s	12.5%	2,534,877	SC 13G/A

Recent SEC filings of ProMIS Neurosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	424B5	Prospectus Filed
Apr 01, 2024	10-K	Annual Report

Peers (Alternatives to ProMIS Neurosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

ProMIS Neurosciences, Inc. News

Latest updates

ProMIS Neurosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet											(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-73.9%	3,548	13,619	17,876	1,498	4,428	6,925	5,382	10,189	13,968	17,747	1,086
Current Assets	-73.9%	3,548	13,619	17,858	1,479	4,409	6,903	5,359	10,162	-	17,714	973
Cash Equivalents	-80.2%	2,497	12,598	16,868	1,223	3,332	5,876	3,921	8,904	13,754	16,944	807
Net PPE	-	-	-	-	-	-	321*	788*	3.00	-	5.00	78.00
Liabilities	-64.8%	3,471	9,866	11,121	10,026	10,607	8,272	4,652	3,479	7,783	12,087	1,883
Current Liabilities	-71.7%	2,646	9,350	9,851	8,739	8,706	6,413	3,099	1,874	-	929	1,883
Long Term Debt	-	-	-	-	-	-	-	-	-	-	3,906	-
Shareholder's Equity	-97.9%	77.00	3,753	6,755	-	-6,179	-1,347	730	6,710	3,738	5,660	-
Retained Earnings	-3.9%	-97,101	-93,465	-89,885	-87,500	-85,200	-80,253	-72,987	-67,000	-	-62,191	-52,401
Additional Paid-In Capital	0.0%	97,549	97,590	97,012	79,368	79,234	79,101	73,988	73,879	-	68,039	51,655
Shares Outstanding	0.4%	18,961	18,885	18,525	8,579	8,579	8,579	7,196	7,196	7,196	7,196	4,829
Float	-	29,700	-	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Cashflow From Operations	-173.8%	-10,291,447	-3,758,238	-2,376,462	-2,147,322	-2,561,654	-4,553,628	-4,635,698	-4,477,789	-3,366,768	-4,046,680	-3,030,266	-	-
Share Based Compensation	1213.4%	63,584	4,841	-	134,191	132,510	138,004	108,584	116,943	124,865	118,149	189,629	126,264	-
Cashflow From Investing	-	-	-	-	-	-	43.00	24.00	9.00	-2,057	95,805	-3,559	-	-
Cashflow From Financing	137.3%	190,274	-510,614	-	-	-	-	-	-	-	445	18,639,825	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,123,778	$ 3,510,252
General and administrative	1,552,873	1,460,419
Total operating expenses	3,676,651	4,970,671
Loss from operations	(3,676,651)	(4,970,671)
Other income (expense):
Change in fair value of financial instruments	(14,132)	(41,665)
Interest expense	(76,775)
Other income	132,470	52,905
Total other income (expense), net	41,563	11,240
Net loss	(3,635,088)	(4,959,431)
Other comprehensive loss
Foreign currency translation adjustment		(4,354)
Comprehensive loss	$ (3,635,088)	$ (4,963,785)
Net loss per share, basic	$ (0.19)	$ (0.58)
Net loss per share, diluted	$ (0.19)	$ (0.58)
Weighted-average shares outstanding of common shares, basic	19,533,976	8,579,284
Weighted-average shares outstanding of common shares, diluted	19,533,976	8,579,284

PMN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 2,496,973	$ 12,598,146
Short-term investments	32,358	32,358
Prepaid expenses and other current assets	1,018,969	988,641
Total current assets	3,548,300	13,619,145
Total assets	3,548,300	13,619,145
Current liabilities:
Accounts payable	1,403,592	7,843,136
Accrued liabilities	1,242,322	1,506,526
Total current liabilities	2,645,914	9,349,662
Share-based compensation liability	716,969	422,002
Warrant liability	108,318	94,185
Total liabilities	3,471,201	9,865,849
Commitments and contingencies
Shareholders' equity (deficit):
Series 2 Convertible Preferred Shares, no par value, unlimited shares authorized, 1,166,667 shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common shares, no par value, unlimited shares authorized, 18,961,116 and 18,885,254 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	97,549,317	97,590,426
Accumulated other comprehensive loss	(371,184)	(371,184)
Accumulated deficit	(97,101,034)	(93,465,946)
Total shareholders' equity (deficit)	77,099	3,753,296
Total liabilities and shareholders' equity (deficit)	$ 3,548,300	$ 13,619,145

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

CEO	Dr. Gail M. Farfel Ph.D.
WEBSITE	promisneurosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	6

ProMIS Neurosciences, Inc. Frequently Asked Questions

What is the ticker symbol for ProMIS Neurosciences, Inc.? What does PMN stand for in stocks?

PMN is the stock ticker symbol of ProMIS Neurosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProMIS Neurosciences, Inc. (PMN)?

As of Thu May 16 2024, market cap of ProMIS Neurosciences, Inc. is 37.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMN stock?

You can check PMN's fair value in chart for subscribers.

What is the fair value of PMN stock?

You can check PMN's fair value in chart for subscribers. The fair value of ProMIS Neurosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProMIS Neurosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProMIS Neurosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether PMN is over valued or under valued. Whether ProMIS Neurosciences, Inc. is cheap or expensive depends on the assumptions which impact ProMIS Neurosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMN.